Skip to main content
. 2015 Oct 16;6(38):41018–41032. doi: 10.18632/oncotarget.5879

Figure 4. Fatostatin predominately suppresses mutant p53-activated SREBP signaling pathways in PCa cells.

Figure 4

A. Heat map showing qPCR analysis of SREBP-1, SREBP-2 and their downstream targets in PC-3 EV, PC-3 R248W and DU145 cells treated with fatostatin for 6 hours. The data were normalized by β-actin. B. Western blot analysis of SREBP-1, SREBP-2 and FASN expression in PC-3 EV, PC-3 R248W and DU145 cells treated with fatostatin for 24 hours. GAPDH was used as a loading control.